Biofrontera (BFRI) Q1 2026 Earnings Transcript

Image source: The Motley Fool.

DATE

Thursday, March 19, 2026 astatine 10 a.m. ET

CALL PARTICIPANTS

• Chief Executive Officer, Chairman, and Founder — Hermann Lubbert

• Chief Commercial Officer — George Jones

• Chief Financial Officer — Eugene Leffler

• Vice President, Investor Relations — Ben Shamsian

Full Conference Call Transcript

Ben Shamsian: Good morning, and invited to Biofrontera Inc.'s First Quarter 2026 Financial Results and Business Update Conference Call. Please enactment that definite accusation discussed during today's telephone by absorption is covered nether the harmless harbor provisions of the Private Securities Litigation Reform Act. We caution listeners that Biofrontera's absorption volition beryllium making forward-looking statements and that existent results whitethorn disagree materially from those stated oregon implied by these forward-looking statements owed to risks and uncertainties associated with the company's business.

All risks and uncertainties are elaborate successful and are qualified by the cautionary statements contained successful Biofrontera's property releases and SEC filings, including the company's quarterly study connected Form 10-Q for the 4th ended March 31, 2026, and the company's yearly study connected Form 10-K for the twelvemonth ended December 31, 2025. Also this league telephone contains time-sensitive accusation that is close lone arsenic of the day of this unrecorded broadcast. Biofrontera undertakes nary work to revise oregon update immoderate forward-looking statements to bespeak events oregon circumstances aft the day of this league call, but arsenic required by law. During today's call, determination volition beryllium references to definite non-GAAP fiscal measures.

Biofrontera believes these measures supply utile accusation for investors yet should not beryllium considered arsenic a substitute for GAAP nor should they beryllium viewed arsenic a substitute for operating results determined successful accordance with GAAP. A reconciliation of non-GAAP to GAAP results is included successful the property merchandise issued contiguous and is disposable connected the company's website astatine www.biofrontera-us.com nether the Investor Relations section. Please note, absorption volition beryllium referencing adjusted EBITDA, a non-GAAP fiscal measure, defined arsenic nett income oregon nonaccomplishment excluding involvement income and expense, income taxes, depreciation and amortization and definite different nonrecurring oregon noncash items, including changes successful just worth of warrant liabilities and stock-based compensation.

With that said, I would similar to present crook the telephone implicit to Hermann Luebbert, CEO, Chairman and Founder of Biofrontera. Hermann?

Hermann Lubbert: Yes. Thank you, Ben, and convey you to everyone joining america this morning. The archetypal 4th of 2026 was beardown crossed our cardinal metrics. We delivered merchandise revenues of $10.1 million, an summation of astir 17% compared to $8.6 cardinal successful the archetypal 4th of 2025. This marks the archetypal afloat 4th reflecting our caller outgo operation pursuing the strategical transaction with Biofrontera AG and the results show that our concern exemplary translation is delivered arsenic planned. These results further show the spot of our commercialized execution and the increasing adoption of Ameluz PDT crossed the dermatology community. George Jones, our CCO, volition travel up astir this successful much detail.